Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis

Radiology 2026 Open access

Read full text
Authors: Sara C. Lewis, Benjamin Wildman‐Tobriner, Jordan Cuevas, Sergio Calle, Ian Bolger, Katherine Wang, Himanshu N. Joshi, Lori Mankowski Gettle, Ju Dong Yang, Ji Hye Min, Claude B. Sirlin, Scott B. Reeder
+2 more Mustafa Rifaat Bashir, Bachir Taouli
DOI: 10.1148/radiol.251497
Cited by: 1
References: 34

Abstract

= .006) analysis. Conclusion Most participants undergoing HCC screening had excellent MRI quality even when US was limited. Quality was adversely affected by obesity (both modalities) and Child-Pugh score (MRI only). ClinicalTrials.gov Identifier: NCT04539717 © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis MRI in cancer diagnosis Liver Disease Diagnosis and Treatment

Publication details

Journal / source
Radiology
Publisher
Radiological Society of North America (RSNA)
Volume
318
Issue
2
Pages
e251497–e251497
Publication date
1 February 2026
Language
EN